Medical Attributes of Hydrastis canadensis - Goldenseal

By Gousfin Hanna and Bhumi Patel
Wilkes University, Wilkes-Barre, PA

July, 2011

Hydrastis canadensis L., goldenseal, is a slow-growing woodland herb that is a member of the buttercup family (Ranunculaceae) (Lonner 2007).  The species is a native of North America, having a range that extends from southern New England, west through the extreme southwestern portion of Ontario, and south to Arkansas and northern Georgia (Catling and Sinclair 2001).  Other common names for this species include yellowroot, orangeroot, eyebalm, eyeroot, goldenroot, ground raspberry, Indian turmeric, yellow puccoon and jaundice root (Kluwer 2009).

According to the Catling and Sinclair (2001), goldenseal is characterized by a bright yellow perennial rhizome. A new hairy stem, approximately 30 cm tall, emerges each year. The hairy green leaves are up to 8 inches in diameter, usually with five lobes.  The species blooms in April or May, producing a single white flower about ½" across, consisting of three early deciduous sepals, no petals, approximately forty spreading stamens, and approximately twelve clustered pistils in the center (Hilty 2011).  In July, a bright red berry containing 10 to 30 black seeds is produced.

Often combined with echinacea, supplements that contain goldenseal currently rank among the top-selling botanicals in the United States (Gurley et. al. 2007).  Much of the plant material sold is derived from wild populations.  As a result of its popularity, this plant is either endangered - or at risk of being endangered - in some parts of the Unted States (Catling & Sinclair 2001; Lonner 2007).

Goldenseal is valued for its rhizome and roots that contain medicinal alkaloids such as berberine, canadine, and hydrastine (Catling & Sinclair 2001; Lonner 2007). These compounds have antibacterial, antifungal, and anti-yeast activity, especially against digestive pathogens (Lonner 2007). Native Americans used the root powder simmered in water as a wash for any kind of eye irritation or infection (Hobbs 1996). Folk medicine also used goldenseal in the treatment of gastrointestinal disturbances, urinary disorders, hemorrhage, and inflammations (Gurley et. al. 2007).  Currently commercial formulations prepared from the root are also used to treat AIDS and enhance the immune system (Catling & Sinclair 2001). Goldenseal capsules are suggested for treating sinus infections, colds, flus, hay fever, eye infections and irritations, mild bowel irritations and inflammations, and upper respiratory and urinary tract infections (Hobbs 1996).

A variety of studies have been conducted to evaluate the effectiveness of goldenseal.  Kaleena and Sharief (2008) performed an in vitro study on human erythrocytes to test its antioxidant properties. Results suggest that the cytoprotection may be due to the plants direct free radical scavenging activity. This can modulate the antioxidant defense system and preserve the functional integrity of the erythrocytes.

Of the three alkaloids found in goldenseal, berberine has been researched the most. According to Serafim et al. (2008), berberine is responsible for apoptosis in different malignant cell lines. At low doses G1 arrest takes place and in higher doses G2 arrest occurs. This shows the multiphase effect of berberine.  Kim et al. (2009) found that berberine inhibits growth of breast cancer cells.

An in vivo study in mice suggests an ethanolic extract of H. canadensis has anti-cancer potentials for use as a supportive complementary medicine in liver cancer (Karmakar et. al. 2010). In contrast, a two year toxicity study found that male and female rats and mice developed liver tumors after treatment with goldenseal root powder. The presence of these tumors could be due to the topoisomerase inhibition properties of berberine (Dunnick et. al. 2011). In addition goldenseal is also capable of affecting human cytochrome P450 activity in the liver (in vivo) (Gurley et. al. 2007).

Another in vivo study in hamsters suggests that berberine is a natural LDL-lowering agent thanks to its ability to stabilize mRNA (Abidi et. al. 2006). In addition, berberine was experimentally found to inhibit certain H1N1 influenza strains and may be effectively treat influenza A infections (Cecil et. al. 2011). Berberine found in the roots and three other flavonoids, sideroxylin, 8-desmethyl-sidedroxylin, and 6-desmethyl-sidedroxylin found in the leaves of goldenseal have antimicrobial potential against Staphylococcus aureus by inhibiting the NorA multidrug resistance pump (Junio et. al. 2011).

Goldenseal should be taken for limited periods, not more than 2 or 3 ten-day cycles every few months, because high doses or those given over an extended time can impair an individual’s digestive system (Hobbs 1996). According to Wolters Kluwer Health (Drugs.com 2009), the recommended dose is 250 mg to 1g three times daily.  Adverse reactions include nausea, anxiety, depression, seizures, or paralysis.  Moreover, commercial preparations of wild harvested goldenseal were found to contain aluminum, cadmium, mercury, and lead due to heavy metal contamination (Lui et. al.2004). 

Hydrastis canadensis L. is a native woodland herb with many medicinal benefits, but it is at risk of being overharvested. It contains compounds that have antibacterial, antifungal, and anti-yeast activity.  Goldenseal is suggested for treating sinus infections, colds, flus, hay fever, eye infections and irritations, mild bowel irritations and inflammations, and upper respiratory and urinary tract infections. Research also demonstrates goldenseal has anti-cancer potential by treating breast and liver cancer. It can also be used to reduce LDL and inhibit disease-causing agents such as the H1N1 virus and Staphylococcus aureus.  Patients should be cautious while administering this botanical due to its wide variety of side effects.


LITERATURE CITED

Abidi, P, W. Chen, F.B. Kraemer, H. Li, & J. Liu. 2006. The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new mechanisms. Journal of Lipid Research. 10:2134-47.

Catling, P. M. & A. Sinclair. 2001. Cultivating the Increasingly Popular Medicinal Plant, Goldenseal: Review and Update. Goldenseal. United States Department of Agriculture.  http://plants.usda.gov/plantguide/pdf/pg_hyca.pdf.

Cecil, C.E., J.M. Davis, N.B. Cech, & S.M. Laster.  2011.  Inhibition of H1N1 influenza A virus growth and induction of inflammatory mediators by the isoquinolie alkaloid berberine and extracts of goldenseal (Hydrastis canadensis). International Immunopharmacology. Epub ahead of print.

Drugs.com 2009. "Complete Goldenseal Information from Drugs.com." Prescription Drug Information, Interactions & Side Effects. Wolters Kluwer Health, 2009. Web. 03 July 2011. http://www.drugs.com/npp/goldenseal.html.

Dunnick, J.K., B. Singh, A. Nyska, J. Peckham, G.E. Kiessling & J.M. Sanders. 2011.  Investigating the potential for toxicity from long-term use of herbal products, goldenseal and milk thistle. Toxicologic pathology. 39(2): 398-409.

Gurley, Bill J., S. Ashley, B.W. Gary, D.K. Williams, B. Philip, C. R. Yates, L. B. Stuart, M. A. Hubbard, Y. Tong & S. Cheboyina. 2007. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 35(2): 240-5.

Hilty, J. 2009. "Goldenseal (Hydrastis canadensis)." Illinois Wildflowers. Web. 3 July 2011. http://www.illinoiswildflowers.info/woodland/plants/goldenseal.htm.

Hobbs, C. 1996. The Dynamic Duo: Echinacea and Golden Seal. Herbal Medicine.  http://www.healthy.net/hwlibraryarticles/hobbs.echydra.htm.

 

Junio, H.A., A.A. Sy-Cordero, K.A. Effefagh, J.T. Burns, K.T. Micko, T.N. Graf, S.J. Richter, R.E. Cannon, N.H. Oberles, & N.B. Cech. 2011.  Synergy-directed fractionation of botanical medicines: A case study with goldenseal (Hydrastis canadensis). Journal of Natural Products.  Epub ahead of print.

Kalenna, P.K. & D. Sharief. 2008. Protective effect of Hydrastis canadensis extract on human erythrocytes: An in vitro study.  Journal of Herbal Medicine and Technology. 2(2): 61-63.

Karmakar, S. R., S. J. Biswas, & A. R. Khuda-Bukhsh. 2010. Anti-carcinogenic potentials of a plant extract (Hydrastis canadensis): I. Evidence from in vivo studies in mice (Mus musculus). Asian Pacific Journal of Cancer Prevention.  11(2): 545-51.

Kim, J.B, J.H. Yu, E. Ko, K.W. Lee, A.K. Song, S.Y. Park, I Shin, W. Han, & D.Y. Nob. 2010. The alkaloid berberine inhibits the growth of Anoikis-resistance MCF-7 and MDA-MB-231 breast cancer cell lines by including cell cycle arrest.  Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 17(6): 436-40.

Lonner, J. 2007. Medicinal Plant Fact Sheet: Hydrastis canadensis / Goldenseal. A collaboration of the IUCN Medicinal Plant Specialist Group, PCA-Medicinal Plant Working Group, and North American Pollinator Protection Campaign. Arlington, Virginia: PCA-Medicinal Plant Working Group.

Lui, C. Z., S. J. Murch, J. C. Jain, & P.K. Saxena. 2004. Goldenseal (Hydrastis canadensis L.); In vitro regenerations for germplasm conservation and elimination of heavy metal contamination. Society for In Vitro Biology. 40(1): 75-79

Serafim, T.L., P.J. Oliveira, V. A. Sardao, E. Perkins, D. Parke, & J. Holy. 2008.  Different concentrations of berberine results in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemotherapy and Pharmacology. 61(6): 1007-18.


This paper was developed as part of the BIO 368 - Medical Botany course offered at Wilkes University during the summer of 2011. Course instructor was Kenneth M. Klemow, Ph.D. (kklemow@wilkes.edu). The information contained herein is based on published sources, and is made available for academic purposes only. No warrantees, expressed or implied, are made about the medical usefulness or dangers associated with the plant species in question.

Return to Plant Summaries page


This page posted and maintained by Kenneth M. Klemow, Ph.D., Biology Department, Wilkes University, Wilkes-Barre, PA 18766. (570) 408-4758, kklemow@wilkes.edu.